Negative trials in ovarian cancer: is there such a thing as too much optimism? - Wikidata - awgldk - TriplyDB

Negative trials in ovarian cancer: is there such a thing as too much optimism?

Negative trials in ovarian cancer: is there such a thing as too much optimism?

http://www.wikidata.org/entity/Q42347314

about

Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016.Does the oncology community have a rejection bias when it comes to repurposed drugs?

P2860

Q37573430-063F765F-2BA0-4E9B-A879-B6B3FC43BB5F Q49884530-642BE7C5-2AB6-4A3B-B13D-38598D47AA7F

P2860

Negative trials in ovarian cancer: is there such a thing as too much optimism?

http://www.wikidata.org/entity/Q42347314

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@en

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@nl

type

label

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@en

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@nl

prefLabel

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@en

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@nl

P1433

Q42347314-066AF978-73B9-4458-BEE5-A029C07254D3

P1476

Q42347314-76F2BF1E-6ACA-4D7D-A151-8C1C2BE3B3C7

P2093

Q42347314-33BEBD00-D156-402A-B3AA-EDFA6D4308C5

P2860

Q42347314-248C4546-F319-4FE6-B2C7-CAE9B3F16A0A

Q42347314-2C13AD4C-3065-4BDD-850E-847CC8742BAE

Q42347314-3059A0A6-BE14-43E8-9451-037EB622B341

Q42347314-5EDA30F9-0B67-4E44-9D6A-E3E561178FC4

Q42347314-5F5C5AD3-296A-4127-A3D6-0C3D99DAB904

Q42347314-6B5B925D-349B-415F-9F3F-2E6706D6DB4C

Q42347314-747F6B13-B394-419D-BC20-4080A1D309F3

Q42347314-77E420AD-2DD4-4399-B5C2-85F8868A0CCF

Q42347314-90F212DE-1F4F-4868-97B0-124C4088FA1D

Q42347314-E2D96639-DE7A-4305-B7D2-BE00E0B1C97D

P304

Q42347314-133FB0E1-0809-4109-B3CB-927E7D01C59E

P31

Q42347314-04dd89d3-0f0d-48fc-85cf-7a5226ad8a25

Q42347314-EBE7A225-E31B-47E6-8F1A-DCE31A752113

P356

Q42347314-02D6589B-B683-42B3-AD7A-1B8956E8ECAC

P478

Q42347314-7D0800C0-F027-44AD-956C-56851D75D4F3

P50

Q42347314-5AF34052-AC18-41D1-941F-185A991BA091

P577

Q42347314-DE4D091E-D1C4-46F0-97DF-B9934D582310

P698

Q42347314-ABBC10BF-3D3A-4DEB-BC93-1AB7C56E7396

P921

Q42347314-4D4F56DF-22DB-41E3-812F-6EFFC8D101BA

P932

Q42347314-897C3419-A145-4713-9FC2-7C800F1693F8

P356

ECANCER.2016.ED58

P1433

Ecancermedicalscience

P1476

Negative trials in ovarian cancer: is there such a thing as too much optimism?

@en

P2093

Vinay Prasad

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

How to use a subgroup analysis: users' guide to the medical literature.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.

P304

ed58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2016.ED58

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27594913

http://www.w3.org/2001/XMLSchema#string

P921

P932

4990052

http://www.w3.org/2001/XMLSchema#string